background
arbidol
antivir
drug
indic
prevent
treatment
type
influenza
infect
kind
acut
respiratori
infect
specif
influenza
group
b
sever
acut
respiratori
syndrom
use
help
prevent
influenza
infect
long
necessari
littl
risk
influenza
mutat
render
less
effect
object
aim
studi
compar
pharmacokinet
properti
toler
determin
bioequival
newli
develop
gener
dispers
tablet
formul
test
brand
capsul
formul
refer
arbidol
mg
healthi
chines
fast
male
volunt
method
openlabel
singledos
randomizedsequ
crossov
studi
conduct
healthi
nativ
chines
male
volunt
elig
subject
randomli
assign
ratio
receiv
singl
dose
test
refer
formul
follow
washout
period
administr
altern
formul
studi
drug
administ
overnight
fast
studi
drug
administr
serial
blood
sampl
collect
hour
administr
plasma
drug
concentr
determin
use
highperform
liquid
chromatographi
coupl
tandem
mass
spectrometri
sever
pharmacokinet
paramet
includ
c
max
max
auc
auc
determin
plasma
concentr
formul
arbidol
use
noncompartment
analysi
formul
consid
bioequival
logtransform
ratio
c
max
auc
within
predetermin
bioequival
rang
establish
state
food
drug
administr
sfda
peopl
republ
china
toler
assess
monitor
vital
sign
blood
pressur
heart
rate
temperatur
electrocardiographi
laboratori
analysi
hematolog
blood
biochemistri
hepat
function
urinalysi
subject
interview
advers
event
result
twenti
subject
enrol
complet
studi
mean
sd
age
year
weight
kg
height
cm
neither
period
sequenc
effect
observ
main
pharmacokinet
properti
test
refer
formul
follow
c
max
ngml
respect
p
ns
median
rang
max
hour
p
auc
ngmlh
p
ns
auc
ngmlh
p
ns
hour
p
ns
ci
logtransform
ratio
c
max
auc
auc
respect
p
within
predetermin
rang
bioequival
advers
event
found
analysi
vital
sign
laboratori
test
report
subject
studi
conclus
studi
healthi
chines
male
volunt
dispers
tablet
formul
capsul
formul
arbidol
met
sfda
regulatori
definit
bioequival
base
rate
extent
absorpt
clin
ther
liu
et
al
healthi
chines
male
nonsmok
volunt
select
studi
subject
sign
informedcons
form
given
detail
inform
aim
restrict
advers
event
could
experienc
result
receiv
studi
drug
studi
entri
subject
underw
interview
regard
occup
smoke
drink
habit
medic
histori
routin
physic
examin
includ
vital
sign
monitor
blood
pressur
heart
rate
temperatur
electrocardiographi
laboratori
analysi
ie
hematolog
blood
biochemistri
hepat
function
urinalysi
ensur
healthi
enough
take
part
studi
subject
histori
evid
renal
gastrointestin
hepat
hematolog
abnorm
acut
chronic
diseas
allergi
chemic
exclud
subject
use
drug
kind
within
week
prior
start
studi
exclud
alcohol
abus
u
alcohol
per
week
u
ml
beer
enrol
subject
random
ratio
use
tabl
random
number
receiv
singl
dose
arbidol
dispers
tablet
test
formul
lot
expir
date
septemb
follow
capsul
refer
formul
lot
expir
date
june
vice
versa
subject
hospit
pm
given
standard
even
meal
g
cook
rice
stapl
food
g
veget
g
meat
ml
water
overnight
fast
requir
state
food
drug
administr
sfda
peopl
republ
china
subject
administ
singl
dose
arbidol
test
refer
formul
ml
water
fast
hour
standard
lunch
standard
even
meal
standard
even
meal
serv
hour
respect
studi
drug
administr
food
permit
period
water
avail
hour
studi
drug
administr
arbidol
antivir
drug
first
market
russia
china
indic
prevent
treatment
influenza
b
respiratori
syncyti
viru
sever
acut
respiratori
syndrom
includ
exacerb
bronchiti
pneumonia
secondari
immunodefici
overal
therapi
chronic
bronchiti
pneumonia
recurr
herpesviru
infect
prevent
postop
infect
stabil
immun
statu
arbidol
might
prevent
contact
entri
virus
cell
inhibit
fusion
viral
lipid
membran
cell
membran
also
report
arbidol
interferoninduc
activ
activ
phagocyt
activ
macrophag
stimul
humor
cellmedi
immun
heighten
bodi
abil
fight
infect
max
singl
dose
arbidol
report
hour
mg
hour
arbidol
metabol
liver
drug
bodi
hour
approxim
excret
unchang
mostli
bile
insignific
amount
excret
kidney
within
first
hour
administr
drug
left
bodi
aim
present
studi
compar
pharmacokinet
properti
determin
bioequival
two
formul
arbidol
newli
develop
gener
formul
dispers
tablet
test
brand
capsul
formul
refer
healthi
chines
fast
male
volunt
openlabel
singledos
randomizedsequ
crossov
studi
conduct
first
affili
hospit
china
medic
univers
shenyang
peopl
republ
china
studi
conduct
accord
principl
declar
helsinki
amend
biomed
research
involv
human
subject
principl
good
clinic
practic
guidelin
clinic
protocol
informedcons
form
approv
local
ethic
committe
china
medic
univers
achiev
c
column
intern
diamet
id
particl
size
shiseido
co
ltd
tokyo
japan
preced
use
guard
column
c
id
phenomenex
inc
torranc
california
column
temperatur
mobil
phase
prepar
mix
formic
acid
ratio
volvol
inject
volum
flow
rate
mlmin
separ
conduct
isocrat
condit
total
run
time
within
minut
electrospray
ioniz
sourc
perform
select
ion
monitor
mode
h
mz
arbidol
h
mz
use
diazepam
select
detect
ion
respect
ms
oper
condit
optim
follow
dri
ga
nitrogen
ga
l
min
curv
desolv
line
temperatur
atom
ga
nitrogen
ga
lmin
detector
voltag
kv
analyt
data
process
use
hplcmsm
solut
shimadzu
biotech
nakagyoku
japan
peak
area
use
quantif
frozen
human
plasma
sampl
thaw
ambient
temperatur
plasma
sampl
spike
diazepam
methanol
na
co
ml
diethyl
ether
vortexmix
minut
centrifug
minut
organ
phase
transfer
anoth
dri
clean
tube
evapor
dryness
thermostat
control
waterbath
slight
stream
nitrogen
residu
dissolv
methanol
use
hplcmsm
analysi
sampl
extract
protect
light
investig
specif
select
hplcmsm
method
blank
human
plasma
sampl
spike
plasma
sampl
subject
sampl
prepar
analyz
chromatographi
find
shown
figur
arbidol
diazepam
retent
time
minut
respect
suggest
endogen
peak
retent
time
arbidol
interf
determin
calibr
curv
arbidol
human
plasma
obtain
use
calibr
standard
prepar
triplic
extract
togeth
blank
sampl
qualiti
control
qc
washout
period
subject
return
clinic
unit
altern
formul
administ
blood
sampl
drawn
complet
crossov
design
studi
blood
sampl
ml
collect
suitabl
forearm
vein
use
indwel
cathet
heparincontain
tube
hour
baselin
hour
studi
drug
administr
blood
sampl
collect
heparin
heparinlock
cathet
discard
ml
blood
blood
sampl
immedi
centrifug
minut
room
temperatur
separ
plasma
plasma
sampl
store
quantit
analysi
determin
plasma
arbidol
concentr
sampl
collect
handl
process
protect
sunlight
method
determin
arbidol
concentr
plasma
use
highperform
liquid
chromatographi
coupl
tandem
mass
spectrometri
hplcmsm
use
describ
elsewher
arbidol
hydrochlorid
diazepam
intern
standard
obtain
nation
institut
control
pharmaceut
biolog
product
beij
peopl
republ
china
puriti
deioniz
water
purifi
use
milliq
water
system
millipor
research
develop
bedford
massachusett
methanol
merck
kgaa
darmstadt
germani
highperform
lc
grade
formic
acid
tedia
co
inc
fairfield
ohio
sodium
carbon
na
co
shandong
aona
chemic
co
ltd
liuyuan
peopl
republ
china
diethyl
ether
sigmaaldrich
corpor
st
loui
missouri
analyt
grade
commerci
avail
blank
plasma
obtain
blood
center
shenyang
peopl
republ
china
bioequival
studi
accord
intern
guidelin
toler
investig
includ
clinician
clinic
pharmacist
nurs
monitor
subject
advers
event
event
also
determin
use
subject
interview
subject
chief
complaint
subject
object
observ
clinician
regard
potenti
presenc
advers
event
allerg
reaction
nausea
diarrhea
dizzi
time
studi
compar
result
vital
sign
monitor
blood
pressur
heart
rate
bodi
temperatur
laboratori
test
hematolog
blood
biochemistri
hepat
function
urinalysi
baselin
hour
studi
drug
administr
day
complet
studi
followup
visit
addit
month
thereaft
selfreport
subject
pharmacokinet
analysi
perform
use
da
version
author
chines
pharmacolog
societi
beij
peopl
republ
china
data
obtain
individu
volunt
subject
noncompartment
pharmacokinet
analysi
auc
auc
c
max
max
elimin
rate
constant
k
e
determin
volunt
c
max
max
obtain
directli
observ
data
k
e
obtain
slope
linear
regress
logtransform
concentr
versu
time
sampl
peak
area
use
quantif
qc
sampl
use
assess
intraday
interday
precis
accuraci
recoveri
prepar
spike
control
human
plasma
arbidol
linear
observ
within
rang
ngml
correl
coeffici
n
lower
limit
quantif
arbidol
ngml
intraday
interday
variat
recoveri
arbidol
determin
human
plasma
shown
tabl
shortterm
stabil
extract
arbidol
sampl
hour
room
temperatur
freezethaw
cycl
stabil
frozen
sampl
frozen
thaw
room
temperatur
freezethaw
cycl
hour
per
cycl
determin
ensur
sampl
stabl
handl
analysi
process
longterm
storag
stabil
plasma
sampl
determin
day
ensur
stabil
frozen
sampl
storag
temperatur
could
affect
reliabl
result
hplcmsm
analysi
result
stabil
arbidol
human
plasma
freezethaw
cycl
shortterm
stabil
longterm
storag
day
shown
tabl
ii
arbidol
stabl
hour
room
temperatur
extract
plasma
sampl
day
within
freezethaw
cycl
plasma
sampl
analyt
method
arbidol
quantif
plasma
sampl
valid
appli
enrol
studi
subject
complet
treatment
period
protocol
violat
abnorm
found
clinic
biochem
paramet
comparison
baselin
versu
endofstudi
assess
mean
sd
pharmacokinet
valu
test
refer
formul
respect
follow
c
max
ngml
p
ns
median
rang
max
hour
p
auc
ngmlh
p
ns
auc
ngmlh
p
ns
hour
p
ns
period
sequenc
effect
detect
pharmacokinet
properti
anova
pharmacokinet
properti
test
refer
formul
summar
tabl
iii
signific
differ
test
refer
formul
auc
auc
c
max
pair
test
except
max
wilcoxon
sign
rank
test
mean
plasma
concentrationtim
profil
formul
administr
singl
oral
dose
arbidol
shown
figur
ci
ratio
testrefer
logtransform
c
max
auc
auc
valu
well
data
termin
portion
curv
calcul
e
auc
calcul
accord
trapezoid
rule
auc
calcul
use
follow
formula
c
last
measur
concentr
test
bioequival
test
refer
formul
analysi
varianc
anova
crossov
design
conduct
logtransform
c
max
auc
auc
ratio
logtransform
c
max
auc
auc
calcul
use
f
score
probabl
exceed
limit
accept
bioequival
establish
sfda
obtain
use
two
test
describ
schuirmann
us
food
drug
administr
formul
consid
bioequival
logtransform
ratio
testrefer
c
max
auc
auc
within
predetermin
bioequival
rang
p
ci
chines
popul
differ
k
e
result
might
relat
differ
race
studi
popul
present
studi
max
test
formul
significantli
shorter
compar
refer
formul
p
find
might
result
differ
prepar
technolog
tablet
test
capsul
refer
formul
result
would
instruct
administr
patient
differ
state
ill
clinic
practic
present
studi
limit
consid
first
small
sampl
size
singledos
openlabel
design
assess
clinic
relev
advers
event
investig
pharmacokinet
data
studi
obtain
healthi
chines
male
volunt
pharmacokinet
properti
arbidol
might
differ
women
infect
patient
clinic
practic
studi
conduct
fast
subject
result
appli
predict
pharmacokinet
properti
arbidol
concurr
administ
food
method
use
assess
toler
perfect
sampl
size
larg
enough
observ
possibl
advers
event
sampl
size
volunt
typic
bioequival
studi
accord
sfda
guidelin
howev
larger
sampl
size
may
need
assess
toler
repres
pharmacokinet
properti
chines
popul
futur
studi
probabl
exceed
limit
accept
bioavail
power
test
shown
tabl
iv
ci
ratio
c
max
auc
auc
respect
within
rang
p
valu
advers
event
observ
clinician
found
analys
vital
sign
monitor
laboratori
analysi
report
subject
studi
find
present
studi
regard
max
hour
respect
consist
review
liu
et
al
report
max
arbidol
minut
hour
studi
drug
administr
glushkov
report
max
hour
administr
dose
max
hour
administr
dose
hour
product
inform
arbidol
capsul
formul
mention
max
hour
hour
comparison
find
previous
publish
studi
suggest
rate
extent
absorpt
differ
dispers
tablet
capsul
formul
elimin
rate
differ
russian
